ACER

Acer Therapeutics Inc. (ACER) | Rumor.io

Acer Therapeutics

ACER

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ACER?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 6

Acer Therapeutics Inc. ($ACER) may benefit from the potential approval of Arimoclomol, a rare disease drug that could generate significant revenue and a possible FDA voucher worth $100M.
The merger with Zevra (ZVRA) could be a positive development for $ACER shareholders, potentially leading to a share price increase, although some investors are skeptical about the deal.
$ACER's pipeline and products have been criticized, with some investors suggesting that the company's value lies in its debt holder's interests, and that the merger is a way for the company to avoid bankruptcy.

Generated by AI

Sentiment

Of the messages about ACER that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	83.05% -0.28
Bearish	—	—	—	16.95% +0.28

Bullish· Sep 1

Acer Therapeutics Inc. has two approved drugs, OLPRUVA and Edsivo, with OLPRUVA expected to take the market over due to its competitive pricing and higher palatability compared to existing treatments.
The acquisition of Acer by Zevra for up to $91M is seen as a positive development, with the potential for Zevra to make significant profits if OLPRUVA becomes a mega success.
Acer's stock price is expected to bounce back and potentially rally to $3, with some investors believing that the company will eventually reach this price due to its potential for growth.

Bearish· Aug 31

Acer Therapeutics Inc. is being sold for a low price, with one post stating the sale is for $15 million at a share price of 64 cents.
The company's management is criticized for making poor business decisions, including the sale of a product to a semi-bankrupt company and the cancellation of an agreement.
The current share price of Acer is low, with one post stating it is less than 1/4 of its previous price, and another post suggesting it could potentially drop to $2.

Generated by AI

Topics

Of the messages about ACER that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Analysts· Aug 17

Acer Therapeutics Inc. ($ACER) was upgraded to Strong Buy by Raymond James with a price target of $46.
Raymond James' upgrade is a positive development for $ACER, but its potential impact on the stock's value is uncertain.
HC Wainwright analysts set a price target of $55 for $ACER, while William Blair reaffirmed its Outperform rating for the company.

Announcements· Aug 31

Zevra Therapeutics ($ZVRA) has agreed to acquire Acer Therapeutics ($ACER) for approximately $91 million, with a potential total value of up to $91 million for Acer stockholders.
The acquisition includes a $15 million upfront payment and up to an additional $76 million in potential cash payments through Contingent Value Rights (CVRs) upon achievement of certain commercial and regulatory milestones.
Acer Therapeutics' stock surged after the announcement, with shares trading higher and reaching a current price of $0.72, up 16.3% pre-market.

Technical Analysis· Dec 9

Acer Therapeutics Inc. ($ACER) is forming a bullish flag, potentially indicating a strong rally.
A break above $1.50 could send $ACER to $3, but bears are attacking the stock, trying to push it back down to $1.30.
$ACER is holding strong above its vwap (volume-weighted average price) of $1.21, and a break of $1.63 could lead to a significant price increase.

Generated by AI

Community

Of the messages about ACER, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	51.34%
Newcomers	—	—	0%	48.66%

Regulars· Mar 22

Acer Therapeutics announces data presented at Society for Inherited Metabolic Disorders Annual Meeting identifying preferred Urea Cycle Disorder treatment attributes, a promising development for the company's treatment of this disorder.
Acer Therapeutics' stock experiences an abrupt price boost on above-average volume, sparking interest among traders.
The company announces a $2.675 million registered direct offering priced at-the-market under Nasdaq rules, a move that may impact its stock price and investor sentiment.

Newcomers· Sep 1

$ACER is experiencing a significant surge, potentially due to a sale agreement with Zevra, but the outcome is uncertain if Zevra pays with stock.
Newcomers are excited about Acer Therapeutics' recent performance, with some users celebrating their profits and others anticipating further gains.
There is speculation about the potential risks and uncertainties of the sale agreement, including the possibility that Zevra may pay with stock, which could impact the outcome.

Generated by AI

News

Zevra Therapeutics: Worthy Of An Initial Holding (NASDAQ:ZVRA)

2mo agoSeeking Alpha

Also Discussed

Investors talking about ACER also mention

#	Name	Attention
1	Delcath Systems, Inc.DCTH	0%new
2	Dyne Therapeutics, Inc.DYN	0%new
3	DarkHorse Technologies Inc.ANY	0%new
4	NRx Pharmaceuticals, Inc.NRXP	0%-0.01
5	SINO - Singularity Future Technology Ltd.	——
6	ALPN - Alpine Immune Sciences, Inc.	——
7	OPGN - OpGen, Inc.	——
8	Savara Inc.SVRA	0%new
9	Euroseas Ltd.ESEA	0%0
10	Vericel CorporationVCEL	0%0